Orexo AB
Research Orexo AB (ORX) on Bullrun: market cap SEK 804.41M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerORX
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 804.41M
- Financial periodFY2024
- RevenueSEK 590.00M
- Revenue growth-7.6%
- Net income-SEK 203.00M
- Free cash flow-SEK 35.70M
- Gross margin87.8%
Valuation Snapshot
latest market cap is SEK 804.41M.
About Orexo AB
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose;
Frequently asked questions
What is Orexo AB's market cap?
Orexo AB's market capitalization is SEK 804.41M.
What does Orexo AB do?
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder;